Diagnostic accuracy of Truenat® MPX assay in comparison to Non-variola Orthopoxvirus RT PCR for diagnosis of mpox disease in Uganda
This laboratory-based cross-sectional study conducted in Uganda demonstrates that the Truenat MPX assay exhibits high diagnostic accuracy, with 96% sensitivity and 99% specificity, for detecting mpox compared to the Non-variola Orthopoxvirus RT-PCR, validating its suitability as a rapid, low-complexity diagnostic tool for resource-limited settings.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the world of infectious diseases, some pathogens are so closely related that they look nearly identical under a microscope, yet they require different responses from doctors and public health officials. One such group is the orthopoxviruses, a family of viruses that includes the smallpox virus, which was eradicated decades ago, and the monkeypox virus, which causes a disease known as mpox. While smallpox is gone, mpox has re-emerged as a significant global health threat, spreading from animal reservoirs to humans and causing outbreaks across continents. To stop these outbreaks, health workers need to know quickly and accurately whether a patient has mpox or a different, less dangerous virus. This requires a diagnostic test that can distinguish between them with high precision. However, the most accurate tests often require expensive equipment and highly trained scientists working in large, central laboratories. In many parts of the world, especially in regions where mpox is most common, patients cannot wait for samples to travel to these distant facilities. The challenge, therefore, is to find a way to perform these sophisticated tests closer to the patient, using simpler machines that are already available in local clinics, without losing the accuracy needed to make life-or-death medical decisions.
A team of researchers in Uganda set out to solve this problem by testing a new tool designed for exactly this purpose. They evaluated a test called the Truenat MPX assay, a molecular test that can detect the genetic material of the mpox virus. The goal was to see if this test could perform as well as the current gold standard used in their country, a complex laboratory test known as the Non-variola Orthopoxvirus RT-PCR, which is highly accurate but requires a sophisticated lab setting. The researchers gathered samples from 150 people who were suspected of having mpox. These samples came from skin lesions, the back of the throat, and the mouth, collected from patients across four different regions of the country. The team tested each sample twice: once with the standard, high-tech laboratory method and once with the new, simpler Truenat device.
The results showed that the new test works remarkably well. When compared against the standard laboratory method, the Truenat MPX assay correctly identified nearly all the people who actually had the virus. Out of the 49 people confirmed to have mpox by the standard test, the new device correctly flagged 47 of them as positive. This means the test missed very few cases. Even more importantly, the test was extremely good at ruling out the disease in people who did not have it. Of the 101 people who were confirmed to be free of the virus by the standard method, the Truenat device correctly identified 100 of them as negative. In the few instances where the two tests disagreed, the researchers re-tested the samples and found that the standard laboratory test was usually the one that had changed its mind, suggesting the new device was often the more reliable of the two in those specific edge cases. The test also produced very few errors or invalid results, with only two out of the 150 samples failing to give a clear answer, a rate that is considered acceptable for medical testing.
What makes this finding particularly significant is that the new test achieved this level of accuracy while being much simpler to use. The Truenat device is a small, portable machine that can be set up in a clinic or a field laboratory, rather than a massive central facility. It can process samples quickly and works with the same types of swabs and skin scrapings that doctors already use. The researchers noted that the test is capable of not just detecting the virus, but also distinguishing it from other similar viruses in the same family, which is crucial for ensuring patients receive the right care. By proving that this simpler tool can match the performance of the complex laboratory standard, the study suggests that health systems can now bring high-quality diagnostic power directly to the communities that need it most. This approach allows for faster identification of cases, which is essential for stopping the spread of the virus and preventing severe illness, all without requiring the massive infrastructure that has historically limited testing in resource-limited settings.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.